Traws Pharma Inc. (TRAW)
NASDAQ (CM) NASDAQ (CM) Primary Summary
TRAW Chart
Traws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug Rigosertib
NEWTOWN, Pa., June 03, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the publication of key clinical efficacy data for rigosertib, a legacy Traws Pharma oncology asset for which development and commercialization partners are being actively sought, in patients with RDEB SCC. The paper, published in the British Journal of Dermatology 1 , details the first clinical trial of any experimental cancer therapeutic in this rare and complicated monogenic disease. The results indicated an overall response rate of 80%, with complete responses in 50% of evaluable patients.
Traws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic Preparedness
NEWTOWN, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced receipt of written responses to questions submitted for a Type B pre-Investigational New Drug Application meeting with the U.S. Food and Drug Administration (FDA, the Agency). The FDA provided feedback on development paths for potential approval of tivoxavir marboxil (TXM) for bird flu and seasonal flu, including on the use of the Animal Rule. The Animal Rule is intended to provide a path to approval in situations when human clinical studies would be unethical or impractical.
Traws Pharma Reports First Quarter 2025 Results and Business Highlights
FDA briefing document submitted April 24, 2025 in support of a meeting to align on pathway for tivoxavir marboxil (TXM, bird flu/seasonal flu) including potential for accelerated approval utilizing the “Animal Rule”
Traws Pharma Inc. Dividends
Traws Pharma Inc. Earnings
| 13 May 2025 Date | | - Cons. EPS | 22.44 EPS |
| 31 Mar 2025 Date | | - Cons. EPS | - EPS |
| 12 Nov 2024 Date | | - Cons. EPS | - EPS |
| 15 Aug 2024 Date | | - Cons. EPS | - EPS |
| 12 Aug 2024 Date | | - Cons. EPS | - EPS |
| 13 May 2025 Date | | - Cons. EPS | 22.44 EPS |
| 31 Mar 2025 Date | | - Cons. EPS | - EPS |
| 12 Nov 2024 Date | | - Cons. EPS | - EPS |
| 15 Aug 2024 Date | | - Cons. EPS | - EPS |
| 12 Aug 2024 Date | | - Cons. EPS | - EPS |
Traws Pharma Inc. (TRAW) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Traws Pharma Inc. ever had a stock split?
Traws Pharma Inc. Profile
| Biotechnology Industry | Healthcare Sector | Dr. Iain D. Dukes DPHIL, M.A., Ph.D. CEO | NASDAQ (CM) Exchange | 68232V884 Cusip |
| US Country | 6 Employees | - Last Dividend | 23 Sep 2024 Last Split | - IPO Date |
Overview
Traws Pharma, Inc. is a clinical stage biopharmaceutical company with a primary focus on developing oral small molecule product candidates. These candidates are aimed at treating respiratory viral diseases and cancer. Originally operating under the name Onconova Therapeutics, Inc., the company underwent a name change to Traws Pharma, Inc. in April 2024. Since its incorporation in 1998, Traws Pharma has been dedicated to advancing a portfolio of novel therapies designed to tackle treatment resistance in these critical areas. Headquartered in Newtown, Pennsylvania, Traws Pharma leverages its expertise in drug development to combat some of the most challenging diseases facing the medical community today.
Products and Services
- TRX01 (travatrelvir) - An investigational Mpro/3CL inhibitor currently in development for the treatment of COVID-19. This small molecule oral candidate is part of Traws Pharma’s endeavor to address the ongoing challenge of treatment resistance in COVID-19 therapeutics.
- TRX100 (viroxavir) - Another promising candidate in Traws Pharma’s portfolio, viroxavir is an endonuclease inhibitor aimed at treating pandemic influenza. It’s part of the company’s broader strategy to provide novel solutions for respiratory viral diseases beyond the COVID-19 pandemic.
- Narazaciclib - This multi-kinase CDK4/6 inhibitor is currently undergoing Phase 1/2 clinical trials in patients with cancer. The trials are exploring its efficacy both with and without the co-administration of letrozole to establish a recommended phase 2 dose. The focus is on further development for the treatment of endometrial cancer, highlighting Traws Pharma’s commitment to advancing cancer treatment options.
- Oral Rigosertib - Administered alone or in combination with other treatments, oral rigosertib is under investigation for its potential in treating various cancers. Its development underscores the company’s ongoing efforts to expand its cancer therapeutics portfolio with innovative and targeted therapies.
Contact Information
